Q BioMed (QBIO) 10-K 26 May 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2022	May 24, 2023
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Nov. 30, 2022
Document Transition Report	false
Entity File Number	000-55535
Entity Registrant Name	Q BIOMED INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	30-0967746
Entity Address, Address Line One	c/o Ortoli Rosenstadt LLP
Entity Address, Address Line Two	366 Madison Avenue
Entity Address, Address Line Three	11.30.2020 3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	588-0022
Title of 12(b) Security	None
Trading Symbol	QBIO
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float		$ 1,300,000
Entity Common Stock, Shares Outstanding		144,094,531
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	New York
Entity Central Index Key	0001596062
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--11-30
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Nov. 30, 2022	Nov. 30, 2021
Current assets:
Cash	$ 49,973	$ 344,009
Accounts receivable	11,535	80,097
Inventory		22,253
Prepaid expenses and other current assets	10,808	13,121
Total current assets	72,316	459,480
Investment	3,143,201
Intangible assets, net	300,000	350,000
Total Assets	3,515,517	809,480
Current liabilities:
Accounts payable	2,132,063	1,345,319
Accrued expenses	1,545,052	954,309
Accrued expenses - related party		71,500
Accrued interest payable	254,686	70,677
Debt	4,109,981	3,053,037
Derivative liabilities	91,158
Total current liabilities	8,132,940	5,494,842
Total Liabilities	8,132,940	5,494,842
Commitments and Contingencies
Stockholders' Deficit:
Preferred stock
Common stock, $0.001 par value; 250,000,000 shares authorized; 84,328,041 and 28,647,788 shares issued and outstanding as of November 30, 2022 and 2021, respectively	84,328	28,648
Additional paid-in capital	56,308,513	53,335,901
Accumulated deficit	(66,095,802)	(64,126,618)
Total Stockholders' Deficit	(4,617,422)	(4,685,362)
Total Liabilities and Stockholders' Deficit	3,515,517	809,480
Convertible Series A Preferred Stock
Stockholders' Deficit:
Preferred stock	2,160,916	2,161,195
Convertible Series B Preferred Stock
Stockholders' Deficit:
Preferred stock	2,874,623	$ 3,915,512
Convertible Series C Preferred Stock
Stockholders' Deficit:
Preferred stock	$ 50,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2022	Nov. 30, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	84,328,041	28,647,788
Common stock, shares outstanding	84,328,041	28,647,788
Convertible Series A Preferred Stock
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	227,998	227,998
Preferred stock, shares outstanding	227,998	227,998
Convertible Series B Preferred Stock
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	345,000	400,000
Preferred stock, shares outstanding	345,000	400,000
Convertible Series C Preferred Stock
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Consolidated Statements of Operations
Net Sales	$ 284,352	$ 195,597
Cost of sales	293,340	246,846
Gross loss	(8,988)	(51,249)
Operating expenses:
General and administrative expenses	3,311,249	6,263,475
Research and development expenses	125,378	1,073,841
Total operating expenses	3,436,628	7,337,316
Loss from operations	(3,445,616)	(7,388,565)
Other (income) expenses:
Interest expense	1,384,465	506,922
Change in fair value of embedded derivatives	(273,782)	304,153
Gain on Mannin conversion	(3,143,201)
Loss on debt extinguishment	384,311	40,910
Loss on issuance of convertible note	12,809
Settlement of registration liability	241,875
Total other expenses	(1,393,523)	851,985
Net loss	(2,052,093)	(8,240,550)
Accumulated dividend on convertible preferred stock	(473,831)	(500,724)
Deemed dividend for induced conversion of convertible preferred stock	(968,160)
Net loss attributable to common stockholders	$ (3,494,084)	$ (8,741,274)
Net loss per share - basic	$ (0.08)	$ (0.33)
Net loss per share - diluted	$ (0.08)	$ (0.33)
Weighted average shares outstanding, basic	44,756,818	26,779,270
Weighted average shares outstanding, diluted	44,756,818	26,779,270

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Preferred stock Series A Preferred Stock	Preferred stock Series B Preferred Stock	Preferred stock Series C Preferred Stock	Common Stock	Additional Paid in Capital Adoption of ASU 2020-06	Additional Paid in Capital	Accumulated Deficit Adoption of ASU 2020-06	Accumulated Deficit	Series B Preferred Stock	Adoption of ASU 2020-06	Total
Beginning balance at Nov. 30, 2020	$ 2,161,980	$ 4,968,368		$ 23,816		$ 47,656,423		$ (55,886,068)			$ (1,075,481)
Beginning balance (in shares) at Nov. 30, 2020	227,998	503,134		23,816,489
Issuance of common stock for cash				$ 100		99,900					100,000
Issuance of common stock for cash (in shares)				100,000
Issuance of common stock and warrants for cash				$ 1,213		908,787					910,000
Issuance of common stock and warrants for cash (in shares)				1,213,333
Issuance common stock for dividend payment on preferred stock	$ (182,398)	$ (340,627)		$ 534		522,491
Issuance common stock for dividend payment on preferred stock (in shares)				533,610
Issuance of common stock to convert notes payable				$ 946		702,668					703,614
Issuance of common stock to convert notes payable (in shares)				945,631
Issuance of common stock to convert Series B preferred stock		$ (1,031,340)		$ 1,245		1,030,095
Issuance of common stock to convert Series B preferred stock (in shares)		(103,334)		1,245,089
Issuance cost related to issuance of convertible notes				$ 35		34,790					34,825
Issuance cost related to issuance of convertible notes (in shares)				35,000
Beneficial conversion feature related to convertible notes						290,967					290,967
Issuance of warrants in conjunction with convertible note						252,683					252,683
Accumulated dividend on preferred stock	181,613	$ 319,111				(500,724)					100,000
Share based compensation for services				$ 759		2,337,821					2,338,580
Share based compensation for services (in shares)				758,636
Net loss								(8,240,550)			(8,240,550)
Ending balance at Nov. 30, 2021	$ 2,161,195	$ 3,915,512		$ 28,648		53,335,901		(64,126,618)			(4,685,362)
Ending balance (in shares) at Nov. 30, 2021	227,998	400,000		28,647,788
Issuance of common stock and warrants for cash				$ 400		99,630					100,030
Issuance of common stock and warrants for cash (in shares)				400,000
Cash proceeds from warrants modification						20,000					20,000
Issuance common stock for dividend payment on preferred stock	$ (182,399)	$ (292,600)		$ 5,497		469,501
Issuance common stock for dividend payment on preferred stock (in shares)				5,497,333
Issuance of common stock to convert notes payable				$ 21,025		2,056,361					2,077,386
Issuance of common stock to convert notes payable (in shares)				21,025,054					25,655,298
Issuance of common stock to convert Series B preferred stock		$ (1,040,000)		$ 25,655		1,982,505					968,160
Issuance of common stock to convert Series B preferred stock (in shares)		(104,000)		25,655,298
Issuance of common stock to extinguish accrued liabilities				$ 676		73,223					73,899
Issuance of common stock to extinguish accrued liabilities (in shares)				676,627
Issuance of common stock to settle derivative liability				$ 545		61,810					62,355
Issuance of common stock to settle derivative liability (in shares)				545,000
Accumulated dividend on preferred stock	182,120	$ 291,711				(473,831)
Share based compensation for services				$ 1,881		390,121					$ 392,002
Share based compensation for services (in shares)				1,880,941							1,880,941
Share based compensation for warrants modification						277,897					$ 277,897
Share based compensation for options modification						182,436					182,436
Reclassification of warrants and options from equity to liability						(907,914)					(907,914)
Deemed dividend for induced conversion of Series B preferred						(968,160)					(968,160)
Issuance of preferred stock to extinguish loan payable			$ 50,000								50,000
Issuance of preferred stock to extinguish loan payable (in shares)			1,000,000
Net loss								(2,052,093)			(2,052,093)
Ending balance at Nov. 30, 2022	$ 2,160,916	$ 2,874,623	$ 50,000	$ 84,328	$ (290,967)	$ 56,308,513	$ 82,909	$ (66,095,802)		$ (208,058)	$ (4,617,422)
Ending balance (in shares) at Nov. 30, 2022	227,998	296,000	1,000,000	84,328,041

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Cash flows from operating activities:
Net loss	$ (2,052,093)	$ (8,240,550)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	392,002	2,338,580
Share based consideration related to warrants modification	299,883
Share based compensation related to stock options modification	211,936
Change in fair value of derivatives	(273,783)
Change in fair value of embedded conversion option		304,153
Accretion of debt discount	922,599	408,009
Amortization expense	50,000	50,000
Settlement on registration liability	241,875
Loss on issuance of convertible note	12,809
Loss on debt extinguishment	384,311	40,910
Changes in operating assets and liabilities:
Accounts receivable	68,563	(80,097)
Prepaid expenses and other current assets	24,566	10,965
Accounts payable and accrued expenses	1,474,728	838,693
Accrued interest payable	184,009	27,301
Net cash provided by (used in) operating activities	1,941,404	(4,302,036)
Cash flows from investing activities:
Investment	(3,143,201)
Net cash used by investing activities	(3,143,201)
Cash flows from financing activities:
Proceeds received from issuance of convertible notes, net	652,731	3,458,900
Proceeds received from issuance of common stock and warrants	100,030	1,010,000
Proceeds received from issuance of notes to related parties		30,000
Cash advances	135,000
Proceeds received for warrants modification	20,000
Repayment of notes to related parties		(30,000)
Net cash provided by financing activities	907,761	4,468,900
Net (decrease) increase in cash	(294,036)	166,864
Cash at beginning of the year	344,009	177,145
Cash at end of the year	49,973	344,009
Supplemental disclosures:
Cash paid for interest to related parties		(441)
Cash paid for income taxes	0	0
Supplemental disclosures for noncash investing and financing activities:
Issuance of common stock to convert notes payable and accrued interest	2,077,386	703,614
Issuance of common stock to convert Series B preferred stock	1,040,000	1,031,340
Deemed dividend for induced conversion of Series B preferred stock	968,160
Accumulated dividend on convertible preferred stock	473,831	500,724
Issuance of common stock for dividend payment on preferred stock	474,799	523,025
Issuance of common stock to extinguish accrued liabilities	73,899
Issuance of common stock to settle derivative liability	62,355
Reclassification of warrants and options from equity to liability due to reassessment under ASC 815	907,914
Adoption of ASU 2020-06	$ 208,058
Beneficial conversion feature related to convertible notes		290,967
Offering cost		$ 69,825

Organization of the Company and

Organization of the Company and Description of the Business	12 Months Ended
	Nov. 30, 2022
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed”), and its wholly owned subsidiaries Q BioMed Cayman SEZC and QBMG Q BioMed Germany UG (collectively, “the Company”), is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or the spinoff of new public companies. The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation and Going

Basis of Presentation and Going Concern	12 Months Ended
	Nov. 30, 2022
Basis of Presentation and Going Concern
Basis of Presentation and Going Concern	Note 2 - Basis of Presentation and Going Concern The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the accounting and disclosure rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. Going Concern The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management will be forced to scale back the Company’s operations or cease its operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty. COVID 19 The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable, but based on the Company’s current assessment, the Company does not expect any material impact on its long-term strategic plans, operations and its liquidity due to the worldwide spread of COVID-19. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world and its assessment of the impact of COVID-19 may change.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Nov. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of warrants on the Company’s stock and the valuation of embedded derivatives within the Company’s convertible notes payable. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At November 30, 2022 and 2022, the Company had a cash balance that is insured by the FDIC limit. The Company had not experienced losses on these accounts. Fair Value of Financial Instruments ​ Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ​ ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended November 30, 2022 and 2021. The respective carrying value of cash and accounts payable approximated their fair values as they are short term in nature. Intangible Assets Intangible assets subject to amortization include acquired intellectual property for a marketable product acquired in November 2018. The intellectual property is being amortized over the estimated life remaining at the time of acquisition, which is 10 years. Intangible assets are monitored for potential impairment whenever events or circumstances indicate that the carrying amount may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. Management has assessed the economic life of the Company’s Metastron asset to be at least equal to its remaining use life of eight years. As such, management modelled the recoverability test using seven years of estimated future cash flows. Based on this projection, the $350,000 net carrying value of the Company’s Metastron asset is fully recoverable and therefore there was no impairment loss as of November 30, 2022 and 2011. Debt Issuance Costs Direct costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying Consolidated Balance Sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the Statement of Operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a binomial model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Common Stock Warrants The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any warrants that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope exception. The Company assesses classification of its common stock warrants at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the criteria for equity or liability classification in the balance sheet. The warrants classified as liability are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the consolidated statements of operations at each period end while such instruments remain outstanding. Revenue Recognition The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. The Company satisfies its performance obligation to deliver products when the customer has received the products, which is when title to the goods has transferred and the customer has control of the products. Payments from customers are generally received within 90 days of when the product is delivered. Because the Company’s agreements have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Stock Based Compensation Effective December 1, 2018, the Company adopted ASU 2018-07, by which the accounting for share-based payments to non-employees and employees is substantially aligned. Non-employee share-based payment awards are measured at grant-date fair value of the equity instruments that the Company is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. There was no cumulative effect of the adoption of this standard. Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award and is recognized over the service period required for the award. Stock-based compensation expense is recognized in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. The Company calculates the fair value of stock options using the Black-Scholes option-pricing model at grant date. General and administrative expenses The significant components of general and administrative expenses consist of stock-based compensation, investor relations fees, consulting, and professional fees. Research and development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made. For the year 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate - Mannin. We incurred a 500k loss between the value of shares received and the amount expended in Research and Development Income Taxes Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties, which only allows the recognition of those tax benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities. As of November 30, 2021 and 2020, the Company reviewed its tax positions and determined there were no outstanding, or retroactive tax positions with less than a 50% likelihood of being sustained upon examination by the taxing authorities, therefore this standard has not had a material effect on the Company. The Company’s policy for recording interest and penalties associated with audits is to record such expenses as a component of income tax expense. There were no amounts accrued for penalties or interest during the years ended November 30, 2022 and 2021. Management is currently unaware of any issues under review that could result in significant payments, accruals, or material deviations from its position. Modification of Equity Classified Awards From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. The classification of stock-based awards, including whether such instruments should be recorded as liabilities or as equity, is reassessed on the modification date. Induced Conversion of Convertible Preferred Stock The Company accounts for gains or losses on extinguishment of equity-classified preferred stock as deemed dividends, to be included in the net loss per common stockholder used to calculate earnings per share. The difference between (1) the fair value of the consideration transferred to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted from (or added to) net loss to arrive at net loss available to common stockholders in the calculation of earnings per share. Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain financial instruments with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, non-employees or directors recognized under ASC 718 are not subject to the sequencing policy. Any modifications of awards (e.g., options or warrants) that remain subject to vesting, or any modifications of awards that continue to be held by active employees, are not subject to the sequencing policy. Modifications of vested awards held by non-employees are subject to the sequencing policy. Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity- classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the impact of adoption the ASU 2021-04 on its condensed consolidated financial statements. ​ Recently Adopted Accounting Standards ​ In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit. ​

Loss per share

Loss per share	12 Months Ended
	Nov. 30, 2022
Loss per share
Loss per share	Note 4 – Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average shares of common stock outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ ​ Potentially dilutive securities November 30, 2022 November 30, 2021 Series A convertible preferred stock 2,280,000 2,280,000 Series B convertible preferred stock ​ 8,457,000 ​ 11,429,000 Series C convertible preferred stock ​ 1,000,000 ​ — Common stock purchase warrants ​ 11,752,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 86,360,000 4,898,000 Potentially dilutive securities 114,299,000 34,809,000 ​

Intangible Asset Acquisition

Intangible Asset Acquisition	12 Months Ended
	Nov. 30, 2022
Intangible Asset Acquisition
Intangible Asset Acquisition	Note 5 – Intangible Asset Acquisition On November 23, 2018, the Company entered into an Asset Sale Agreement (“ASA”) with GE Healthcare Limited (“GE”) whereby the Company acquired GE’s radiopharmaceutical drug, Metastron® and all related intellectual property including, but not limited to sales and distribution data, market authorizations and trademarks for Metastron® in various countries in exchange for an upfront payment of $0.5 million, a one-time milestone payment based on future sales, and royalty payments based on future sales. The Company did not acquire any workforce, manufacturing, inventory, sales agreements, or distribution agreements associated with Metastron®. The first commercial sale of Metastron™ by the Company will occur only after the successful transfer or assignment of all intellectual property, material sales and distribution data, technical transfer, and the establishment of new manufacturing sites by the Company and under the appropriate regulatory filings required by the jurisdictions in which Metastron™ is sold. The acquired assets are concentrated in a single asset and the set is not considered a business. As such, the transaction is recognized as the acquisition of a finite-lived intangible asset. The one-time milestone payment based on future sales, and royalty payments based on future sales will be recognized when the payments are probable and estimable, which is expected to be when the related sales targets are achieved and the payments payable to GE. The acquired asset is being amortized on a straight-line basis over its estimated 10-year life. Amortization expense for the years ended November 30, 2022, and 2021 was ​ ​ ​ ​ ​ Year ended November 30, ​ ​ 2023 ​ ​ 50,000 2024 ​ 50,000 2025 ​ 50,000 2026 ​ 50,000 2027 ​ 50,000 Thereafter ​ 50,000 ​ ​ $ 300,000 ​

Investment

Investment	12 Months Ended
	Nov. 30, 2022
Investment
Investment	Note 6 – Investment For the year ended November 30, 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate - Mannin. We incurred a $500k loss between the value of shares received and the amount expended in Research and Development.

Debt

Debt	12 Months Ended
	Nov. 30, 2022
Debt
Debt	Note 7 – Debt The table below summarizes outstanding convertible notes as of November 30, 2022, and 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ November 30, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ Principal value of 2021 Debentures ​ $ 2,408,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 1,099,000 ​ 867,000 Debt discount ​ (70,000) ​ (1,320,000) 2021 Convertible notes payable, net ​ 3,437,000 ​ ​ 3,053,000 Principal value of 2022 Debentures ​ ​ 560,000 ​ ​ — Fair value of bifurcated contingent put option ​ ​ 333,000 ​ ​ — Debt discount ​ ​ (305,000) ​ ​ — 2022 Convertible notes payable, net ​ ​ 588,000 ​ ​ 3,053,000 Cash advances ​ ​ 85,000 ​ ​ — Total carrying value of convertible notes payable ​ $ 4,110,000 ​ $ 3,053,000 ​ 2022 Convertible Notes Payable 2022 Debentures July 2022 Debenture On July 1, 2022, the Company entered into a Securities Purchase Agreement with an accredited investor (“DL”) pursuant to which the Company issued to DL a Convertible Promissory Note (the “DL Note”) in the aggregate principal amount of $119,888 . The DL Note includes an original issue discount of $16,888 (includes $1,250 due diligence fee retained by DL). The Company also incurred an additional $3,000 of issuance cost resulting from the payment of the lender’s legal fees. The DL Note has a maturity date of July 1, 2023, and the Company has agreed to pay interest on the unpaid principal balance of the DL Note at the rate of 10.0% per annum from the date on which the DL Note is issued (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise. The Company has the right to prepay the DL Note, provided it makes a payment including a prepayment to DL as set forth in the DL Note. The outstanding principal amount of the DL Note may not be converted prior to the period beginning on the date that is 180 days following the Issue Date. Following the 180th day, DL may convert the DL Note into shares of the Company’s common stock at a conversion price equal to 80% of the average of 3 lowest trading price with a 10-day look back immediately preceding the date of conversion. The contingent share-settled redemption feature, contingent acceleration upon merger, acquisition, and event of default within the DL Note are all contingent put options that are required to be bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of put option on the merger, acquisition, and event of default by estimating the probability of the occurrence of triggering date (the “Probability factor”) and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ July 1, 2022 ​ Strike price ​ $ 0.05 Terms (years) ​ 1.0 Volatility ​ 138 % Risk-free rate ​ ​ 2.8 % Dividend yield ​ 0 % Probability factor ​ 20 % ​ The aggregate fair value of the embedded put option on the issuance date was approximately $104,000, which exceeded the net proceeds of $100,000, resulting in an approximate loss of $4,000 upon the on issuance of the convertible note. August 2022 Debenture On August 10, 2022 (the “Effective Date’), the Company entered into a Securities Purchase Agreement with an accredited investor (“the Lender”) pursuant to which the Company issued to the Lender a Convertible Promissory Note (the “August Note”) in the aggregate principal amount of $275,000 for a purchase price of $250,000 . The August Note has a maturity date of February 6, 2023, and the Company has agreed to pay interest on the unpaid principal balance of the August Note at the rate of 10.0% per annum. Upon the later of the date the obligations under this Note are satisfied or the 6-month anniversary and for 30 days thereafter, the Lender has the exclusive right to elect conversion of any original issue discount or interest amount due under this August Note, into shares of the Company’s common stock at a conversion price per share equal to $0.035 . The conversion option does not apply to the principal amount. The conversion option and contingent put upon an event of default are required to be bifurcated as a single compound embedded derivative at fair value under ASC 815, because it is not considered to be classified in stockholders’ equity. The subsequent changes in fair value are recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value with the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ August 10, 2022 ​ Strike price ​ $ 0.04 Terms (years) ​ 0.5 Volatility ​ 200 % Risk-free rate ​ ​ 3.1 % Dividend yield ​ 0 % ​ The aggregate fair value of the conversion option on the issuance date was approximately $23,000, which was recognized as an additional debt discount. As additional consideration for making the August Note, the Company agreed to issue 300,000 unregistered common shares within 10 business days to the Lender (the “Commitment shares”). The commitment to issue the shares was valued at the Effective Date fair value of approximately $11,000 and recognized as an additional debt discount. The commitment is a forward contract, recognized at fair value, as a result of applying the Company’s sequencing policy, and recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations until settled on August 24, 2022. September 2022 Debenture On September 15, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $102,637. The September Debenture has a maturity date of xxx, 2023, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The September Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. October 2022 Debenture On October 18, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “October Debenture”) in the principal amount of $63,250. The October Debenture has a maturity date of xxx, 2023, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The October Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. November 2022 Debenture On November 22, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “November Debenture”) in the principal amount of $62,387. The November Debenture has a maturity date of xxx, 2023, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The November Debenture carries an interest rate of 6% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 22% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. 2021 Debentures February Debenture On February 12, 2021, the Company issued a debenture for $0.5 million (the “February Debenture”) pursuant to a securities purchase agreement with an accredited investor dated February 12, 2021. The February Debenture may be converted at any time on or prior to maturity at the lower of $1.15 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2020 Debenture, the conversion price may never be less than $1.00. The debenture has a maturity date of February 12, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on issuance, the Company paid to the holder a commitment fee equal to 2% of the amount of the debenture. The aggregate fair value of the contingent put options on the issuance date was approximately $28,000, which was recognized as an additional debt discount. On January 21, 2022, the Company issued 1,055,000 shares of common stock to convert $0.5 million of outstanding debt and interest and extinguished $95,000 of embedded derivative liability upon the conversion. The conversion price was reduced to $0.50. The Company recognized a loss on debt extinguishment of approximately $232,000 as a result of the reduction of conversion price for the nine months ended August 31, 2022. July Debenture On July 26, 2021, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “July Debenture”) in the principal amount of $806,250 and a warrant to purchase up to 645,000 shares of common stock (the “Warrant”) for a total purchase price of $750,000. The Company also paid $18,750 for the lender’s legal fee. The July Debenture has a maturity date of April 26, 2022, provided that in case of an event of default, the debenture may become at the holder’s election immediately due and payable. The July Debenture carries an interest rate of 10% per annum, provided that any principal or interest which is not paid when due shall bear interest at the rate of 15% per annum from the due date until payment (the “Default Interest”). The Company may prepay the Debenture at 120% of the outstanding aggregate principal amount within the first 60 days of issuance and at 130% of the sum of the outstanding principal amount, the accrued and unpaid interest on the unpaid principal amount and any Default Interest from 61 to 180 days after issuance. The holder may convert the July Debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The “Variable Conversion Price” shall equal, subject to an initial floor price of $0.35 (the “Floor Price”), the lower of $1.00 and 85% of the average of the four (4) lowest VWAPs during the 20 Trading Days prior to the date of such calculation. The initial Floor Price shall be readjusted to $0.10 if following the Issue Date, VWAP of the Company shall be less than $0.35 for a total of ten days. The Warrant has an exercise price of $1.25 and may be exercised in cash or via cashless exercise, exercisable for five ( 5 The contingent share-settled redemption feature and contingent prepayment provision within the July Debenture are all contingent put options that are required to be bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value with the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ July 1, 2022 ​ Strike price ​ $ 0.05 Terms (years) ​ 1.0 Volatility ​ 138 % Risk-free rate ​ ​ 2.8 % Dividend yield ​ 0 % Probability factor ​ 20 % ​ The aggregate fair value of the contingent put options on the issuance date was approximately $209,000, which was recognized as an additional debt discount. ​ On December 15, 2021, the Company and the holder entered into a Mutual Release Agreement pursuant to which the holder agreed to add the $241,875 to the outstanding principal balance of July Debenture, for no consideration received by the Company, in order to resolve a breach of certain registration provisions of the securities purchase agreement. ​ The July Debenture is past maturity and is currently in default. However, the Company has not received any default notice from the holder. ​ During the year ended November 30, 2022, the Company issued an aggregate 3,633,862 shares of common stock to convert approximately $413,000 of outstanding debt and extinguished approximately $159,000 embedded derivative liability upon the conversion. The Company recognized a loss on debt extinguishment of approximately $152,000 as a result of the reduction of conversion price for the year ended November 30, 2022. ​ September Debenture On September 29, 2021, the Company entered into a securities purchase agreement with an accredited investor (“Lender”), pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $2,200,000 with twelve-months term. The September Debenture includes an original issue discount of $185,000 and $15,000 for the payment of the Lender’s legal fees and carries an interest rate of 6% per annum. The Company also incurred other issuance costs of $247,350. On October 26, 2021, the September Debenture maturity date was extended for an additional 3 months to December 20, 2022. The Company may prepay the September Debenture at 105% of the outstanding aggregate principal amount plus accrued interest within the first 60 days of issuance, at 112% of the outstanding aggregate principal amount plus accrued interest from 61-120 days after issuance and at 124% of the outstanding aggregate principal amount plus accrued interest from 121-180 days after issuance. The Debenture may not be prepaid after 180 days. The Lender has the right to convert all or any amount of the outstanding aggregate principal amount at any time at a fixed conversion price of $1.00 per share. The conversion price after six months shall be fixed at $0.50 per share. However, in the event the Company’s Common Stock trades below $0.50 per share for more than ten (10) consecutive trading days, the Lender is entitled to convert all or any amount of the outstanding aggregate principal amount into shares of the Company’s Common Stock at a Conversion Price for each share of Common Stock equal to 85% of the average of the 4 lowest VWAP’s in the prior 20 trading days. As a result of entering into the “September Debenture”, for which such instruments contained a variable conversion feature with no floor, the Company has adopted sequencing policy (see Note 3). The contingent share-settled redemption feature and contingent prepayment provision within the September Debenture are all contingent put options that are required to be bifurcated as a single compound embedded derivative at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value with the following key inputs: ​ ​ ​ ​ ​ ​ ​ September 29, 2021 Strike price ​ $ 0.50 ​ Terms (years) ​ ​ 1.0 ​ Volatility ​ ​ 66 % Risk-free rate ​ ​ 0.1 % Dividend yield ​ ​ — % ​ The aggregate fair value of the contingent put options on the issuance date was approximately $278,000, which was recognized as an additional debt discount. ​ On April 8, 2022, the Company issued 245,000 shares of common stock as commitment shares pursuant to the securities purchase agreement. The commitment to issue the shares was valued at the Effective Date fair value of approximately $177,000 and recognized as an additional debt discount. The commitment is a forward contract, recognized at fair value, as a result of applying the Company’s sequencing policy, and recognized at fair value with changes in fair value recognized in the Company’s Condensed Consolidated Statements of Operations until settled on April 8, 2022. ​ For the year ended November 30, 2022, the Company issued 21,025,054 shares of common stock to convert approximately $305,000 of outstanding debt and extinguished $146,000 of embedded derivative liability upon the conversion. ​ The fair value of the contingent put option in all outstanding debentures with the feature are revalued as of November 30, 2022 and 2021 based on the following weighted average key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ November 30, 2022 November 30, 2021 ​ Strike price ​ $ 0.55 ​ $ 0.71 ​ Terms (years) ​ ​ 0.3 ​ ​ 0.8 ​ Volatility ​ ​ 200 % ​ 71 % Risk-free rate ​ ​ 2.9 % ​ 0.2 % Dividend yield ​ ​ 0 % ​ 0 % ​ The following table presents changes in Level 3 liabilities measured at fair value for the years ended November 30, 2022, and 2021. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (amounts are rounded to nearest thousand). ​ ​ ​ ​ ​ Balance December 1, 2020 $ — Additional derivative liability ​ 603,000 Debt extinguishment ​ (40,000) Change in fair value ​ ​ 304,000 Balance November 30, 2021 ​ $ 867,000 Issuance of convertible notes ​ ​ 271,000 Debt extinguishment ​ ​ (425,000) Change in fair value ​ 721,000 Balance November 30, 2022 ​ $ 1,434,000 ​ Debt Conversion ​ The following table summarizes debt conversion during the years ended November 30, 2021, and 2020 (amounts are rounded to nearest thousand): ​ Debt Amendment ​ On October 26, 2021, the Company entered into an extension agreement with the holder of September 2021 Debenture (the “Holder”) to extend the maturity date from September 30, 2022, to December 29, 2022. The amendment was recognized as a troubled debt restructuring. ​ On July 22, 2021, the Company entered into an amendment agreement to the securities purchase agreement with the Holder, pursuant to which, the floor price of the 2020 Debenture was reduced to $0.50 per share. Additionally, the maturity date of the 2020 Debenture was extended to December 31, 2021. The amendment was recognized as a debt extinguishment, resulting in a gain on debt extinguishment of approximately $15,000. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years ended ​ November 30, 2022 November 30, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 252,000 ​ $ 96,000 Accretion of debt discount ​ 1,073,000 ​ 408,000 Other ​ 60,000 ​ 3,000 Total interest expense ​ $ 1,385,000 ​ $ 507,000 ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Nov. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 8 – Commitments and Contingencies Equity Financing ​ On May 5, 2021, the Company entered into an agreement with Aedesius Holdings Ltd. (“Aedesius”) pursuant to which the Company has agreed with Aedesius that the Company would sell it up to 16,000,000 units (the “Units”) for a total aggregate of up to $20,000,000. ​ Aedesius failed to perform on its obligation and to date has not invested any monies in the Company. As a result, the Company has terminated any and all rights with respect to future fundings and will pursue whatever rights and remedies the Company has at its disposal for breach of contract. ​ Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. As previously reported, on July 12, 2022, the Company was notified that WSI PBG, LLC (“WSI”) filed a complaint against the Company seeking to recover $196,216 in unpaid consulting fees, plus costs and expenses of litigation. The Company elected not to litigate this suit so as not to increase its liability exposure. Not unexpectedly, on August 24, 2022, WSI obtained a judgment against the Company in the amount of $203,784 . The Company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfaction of this Judgment over a limited period of time. On July 19, 2022, we received notice that the Activus Group (“Activus”) filed a complaint for fees it alleges are due in the amount of $129,600 plus fees and expenses for consulting services provided by Activus as a result of an agreement between the parties. We have not filed an answer and are currently determining our next steps in settlement. On August 15, 2022, the Company received notice that another of its unpaid contractors, Diligent Health Solutions, LLC. (“DHS”), had filed suit against the Company seeking $106,000 in unpaid consulting fees. Here, too, the Company elected not to litigate this suit so as not to increase its liability exposure. As a result of the foregoing, DHS obtained a default judgment against the Company in the amount of $111,000 . The company is exploring its options in addressing this judgment, including terms of settlement that would result in a satisfy of this Judgment over a limited period of time. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. On March 11, 2022, the Company entered into an engagement letter agreement (“Agreement”) with EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”) to effectuate the Corporation’s Firm Commitment Public Offering and Uplisting and to engage EF Hutton to act as the placement agent for a bridge or other private offering consisting of approximately $2 million. The Company shall be responsible for EF Hutton’s external counsel’s legal costs irrespective of whether the Offering is consummated or not, subject to a maximum of $50,000 in the event that there is not a Closing. The Company incurred $15,000 of expense for the year ended November 30, 2022, and no payment was made as of November 30, 2022. Lease Agreement ​ In December 2016, one of our subsidiaries entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ended in December 2019, and the Company has renewed its office lease agreement for another three years with the same terms. This agreement does not identify a specific asset and does not convey the use of substantially all of the shared office capacity. As such, this agreement does not contain a lease under ASC 842. The Company recognizes monthly license payments as incurred over the term of the arrangement. Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Consolidated Statements of Operations as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2022 2021 Rent expense ​ $ 30,000 ​ $ 30,000 ​ License Agreements Mannin On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License. On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021, in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019. On September 1, 2020, the Company further amended the license agreement allowing Mannin to grant an exclusive license to Mannin GmbH (its wholly owned German subsidiary) in order fully take advantage of the German government grant to Mannin. The agreement also confirms our ongoing investment into the Tie2 platform to create, and therefore maintain economic value for us and our shareholders. The Company has agreed to contribute funds in Mannin GmbH. We shall pay Mannin $1.5 million in cash payable in three instalments, thereof $0.7 million of which has been paid, $0.4 million of which was due on December 31, 2020, and $0.4 million to be paid by June 30, 2021. In addition, we paid Mannin $0.75 million in shares of our common stock valued as of June 15, 2020, in full satisfaction of R&D payables, contracted by Mannin in development of the Tie2 platform. We continue to have the right to 100% of the revenues derived from the Mannin Tie2 technology platform, until such time that Mannin and its subsidiaries have independently raised at least $2.0 million in funds, at which time the parties have agreed to a profit share structure reducing our future capital commitments to Mannin R&D. During the years ended November 30, 2022, and 2021, the Company incurred approximately $0.1 and $1.1 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License. For the year ended November 30, 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate - Mannin. We incurred a $500k loss between the value of shares received and the amount expended in Research and Development. Washington University On March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones: ● The first commercial sale of a companion diagnostic product; ● Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent; ● PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and ● The first commercial sale of a diagnostic product. In addition to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Nov. 30, 2022
Related Party Transactions
Related Party Transactions	Note 9 – Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Consolidated Statements of Operations as follows (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years ended ​ November 30, 2022 November 30, 2021 Consulting and legal expenses ​ $ 308,000 ​ $ 420,000 ​ On February 1, 2021, the Company issued 35,000 shares to Mr. Rosenstadt, the Company’s Chief Legal Officer and director, for his services performed in connection with December 2020 financing. The fair value was approximately $35,000, which was recorded as part of debt issuance cost to the 2020 Debenture (see note 5). On April 16, 2021, the Company entered into two unsecured promissory note agreements (the “Notes”) with certain management personnel for an aggregate principal amount of $30,000. The Notes bear interest at 5% per annum and are payable by August 31, 2021. During the quarter ended August 31, 2021, the Company made full repayment of $30,000 to the management personnel, including all outstanding interest. ​ On May 29, 2022 the company issued 250,000 shares at a nominal value of 10c per share to Mr. Rosenstadt , the company’s Chief Legal Officer and director, in lieu of cash for his monthly services. On May 29, 2022, the company issued 200,000 shares at a nominal value of 10c per share to Mr Corin, the company’s Chief Executive Officer, as partial payment of his monthly salary in lieu of cash.

Stockholders' Deficit (Deficit)

Stockholders' Deficit (Deficit)	12 Months Ended
	Nov. 30, 2022
Stockholders' Deficit
Stockholders' Deficit	Note 10 - Stockholders’ Deficit As of November 30, 2022, and 2021, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Preferred Shares The original issue price and the liquidation value per share, as of November 30, 2022, of each class of preferred stock is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price ​ Liquidation Value ​ Per Share Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.25 Series C Preferred Share ​ $ 0.05 ​ $ — ​ During the years ended November 30, 2022 and 2021, the Company issued total 5,497,333 shares and 533,610 shares of common stock as dividend payment on Series A and Series B preferred stock for the amount of $0.5 million and $0.5 million, respectively. During the year ended November 30, 2022, the Company issued 25,655,298 shares of common stock to convert 104,000 shares of Series B preferred stock. The Company recognized deemed dividend for the difference between the carrying amount of the preferred stock and the fair value of the common stock exchanged for such preferred stock of approximately $1 million for the year ended November 30, 2022, in the Consolidated Statements of Operations. During the year ended November 30, 2022, the Company issued 1,000,000 shares of Series C preferred stock in the amount of $50,000 for settlement of an amount due to officers and directors. The Company had accumulated dividends payable on the Preferred Shares of approximately $0.5 million and $0.1 million as of November 30, 2022, and 2021, respectively. Common Shares 2022 Activities Issuance of common shares for services ​ During the year ended November 30, 2022, the Company issued an aggregate of 1,880,941 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $88,000 based on the estimated fair market value of the stock on the date of grant. The Company also recognized approximately $240,000 related to the vesting of stock options and restricted awards. The $240,000 was recognized within general and administrative expenses in the accompanying Consolidated Statement of Operations for the year ended November 30, 2022. ​ Issuance of common shares for cash ​ On February 14, 2022, the Company entered into a series of securities purchase agreements for the sale of 400,000 units at a $0.25 unit sales price. The Company raised $100,000 in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $0.50. The common warrants issued on February 22, 2022, have a fair value of $0.28 per share, see Note 11. ​ Issuance of common shares for debt conversion ​ During the year ended November 30, 2022, the Company issued 21,025,054 shares of common stock to convert approximately $1,246,000 of outstanding debt and interest and extinguished approximately $365,000 of embedded derivative liabilities Additionally, the Company reversed approximately $118,000 of unamortized debt discount upon the conversion. The Company recognized approximately $384,000 ​ Issuance of common stock for preferred stock conversion ​ During the year ended November 30, 2022, the Company issued 25,655,298 shares of common stock to convert approximately 104,000 shares of Series B preferred stock. ​ Issuance of common shares for preferred stock dividends ​ During the year ended November 30, 2022, the Company issued ​ 2021 Activities ​ Issuance of common shares for services During the year ended November 30, 2021, the Company issued an aggregate of 758,636 shares of the Company’s common stock to various vendors for advisory services, valued at approximately $0.7 million based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. ​ Issuance of common shares for cash On February 26, 2021, the Company issued 100,000 shares of common stock for cash proceeds of $0.1 million. On May 20, 2021, the Company entered into a series of securities purchase agreements for the sale of 1,213,333 units at a $0.75 per unit sales price. The Company raised approximately $0.9 million in cash. Each unit consisted of one common share and one warrant to purchase one share of common stock at an exercise price of $1.25. The common warrants issued on May 20, 2021 have a fair value of $0.80 per share. Issuance of common shares for debt conversion During the year ended November 30, 2021, the Company issued 945,631 shares of common stock to convert $0.7 million of outstanding debt and interest. Issuance of common shares for preferred stock conversion Between January and February 2021, the Company issued 1,245,089 shares of common stock to convert approximately 103,000 shares of Series B preferred stock. Financing Agreements On September 15, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “September Debenture”) in the principal amount of $102,637. On October 18, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “October Debenture”) in the principal amount of $62,250 On November 22, 2022, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company sold a convertible debenture (the “November Debenture”) in the principal amount of $62,387.

Warrants and Options

Warrants and Options	12 Months Ended
	Nov. 30, 2022
Warrants and Options
Warrants and Options	Note 11 - Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at November 30, 2022 and 2021 and the changes during the period then ended (warrants amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Warrants Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ $ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.23 ​ ​ — Forfeited/expired ​ (932,000) ​ ​ — ​ — ​ ​ — Outstanding and exercisable at November 30, 2022 ​ 11,220,000 ​ $ 1.01 ​ 3.8 ​ $ — ​ Grant date fair value of all outstanding warrants was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ ​ 2022 2021 ​ Strike price ​ $ 1.25 ​ $ 1.25 ​ Term (years) ​ 5.0 ​ ​ 5.0 ​ Volatility ​ 114 % ​ 114 % Risk-free rate ​ 0.4 % ​ 0.8 % Dividend yield ​ 0.0 % ​ 0.0 % ​ Modification date fair value of all outstanding warrants was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 1.77 ​ $ 2.51 ​ Term (years) ​ ​ 3.5 ​ 0.8 ​ Volatility ​ ​ 123 % 77 % Risk-free rate ​ ​ 0.5 % ​ 0.4 % Dividend yield ​ ​ 0.0 % 0.0 % ​ Warrants issued on February 22, 2022, were classified as liabilities. The fair value of the warrants on grant date was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ February 22, 2022 ​ Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % ​ Modification of Warrants On February 1, 2022, the Company modified an aggregate of 245,625 warrants (the “Warrants”) that were originally granted to certain investors and consultants. The exercise price of the Warrants was reduced to $0.65 per share and the maturity dates of the Warrants were extended until August 1, 2024. The Company received $20,000 cash from one of the investors as consideration for this modification. The Company immediately recognized approximately $17,000 incremental stock-based compensation on February 1, 2022 based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ ​ 2.5 ​ 2.1 ​ Volatility ​ ​ 135 % 127 % Risk-free rate ​ ​ 1.0 % ​ 1.0 % Dividend yield ​ ​ 0.0 % 0.0 % ​ Between April and May 2022, the Company modified an aggregate of 4,765,807 warrants (the “Warrants”) that were originally granted to certain investors and officers during 2017 and 2021. The exercise price of the Warrants was reduced to between $0.50 and $0.65 per share and the maturity date of the Warrants were extended for an additional 5 years. The Company immediately recognized approximately $261,000 incremental stock-based compensation during the quarter ended May 31, 2022, based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.51 ​ $ 1.76 ​ Term (years) ​ ​ 6.9 ​ 2.1 ​ Volatility ​ ​ 118 % 128 % Risk-free rate ​ ​ 2.7 % ​ 2.2 % Dividend yield ​ ​ 0.0 % 0.0 % ​ On August 31, 2022, the Company modified an aggregate of 3,608,641 warrants (the “Warrants”) that were originally granted to certain officers during 2017 and 2021. The exercise price of the Warrants was reduced to $0.10 per share. The Company immediately recognized approximately $22,000 incremental stock-based compensation during the quarter ended August 31, 2022, based on the following weighted average assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.10 ​ $ 0.50 ​ Term (years) ​ ​ 2.7 ​ 2.7 ​ Volatility ​ ​ 151 % 151 % Risk-free rate ​ ​ 3.5 % ​ 3.5 % Dividend yield ​ ​ 0.0 % 0.0 % ​ The new warrants issued in February 2022 and warrant modifications, described above, resulted in reclassifying such modified warrants to purchase an aggregate of 5,461,432 common shares from equity to liability as a result of applying the reassessment under ASC 815. The warrants are subsequently recognized at fair value with changes in fair value recognized in the Company’s Consolidated Statements of Operations. ​ Options issued for services The following represents a summary of all outstanding options to purchase the Company’s common stock at November 30, 2022 and 2021 and the changes during the period then ended (options amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued 3,000,000 ​ ​ 0.10 5.0 ​ ​ — Forfeited/expired ​ — ​ ​ — ​ — ​ ​ — Outstanding at November 30, 2022 ​ 7,450,000 ​ $ 0.10 ​ 6.5 ​ $ — Exercisable at November 30, 2022 ​ 5,200,000 ​ $ 0.10 ​ 7.5 ​ $ — ​ Fair value of all options issued as of November 30, 2021was calculated with the following key inputs: ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2021 Strike price ​ $ 0.45 ​ Term (years) ​ 5.0 ​ Volatility ​ 111 % Risk-free rate ​ 1.2 % Dividend yield ​ 0.0 % ​ Stock-based Compensation The Company recognized general and administrative expenses of approximately $ million and $2.3 million as a result of the shares, outstanding warrants and options issued to consultants and employees during the years ended November 30, 2022 and 2021, respectively. As of November 30, 2021, the estimated unrecognized stock-based compensation associated with these agreements is approximately $210,000 and was fully recognized by November 30, 2022.

Income Taxes

Income Taxes	12 Months Ended
	Nov. 30, 2022
Income Taxes
Income Taxes	Note 12 – Income Taxes At November 30, 2022, the Company has a net operating loss (“NOL”) carryforward for Federal and state income tax purposes totaling approximately $33 million available to reduce future taxable income. Of this amount, approximately $10 million will begin to expire in 2034. Under the Tax Cuts and Jobs Act, all NOLs incurred after December 31, 2017, are carried forward indefinitely for federal tax purposes. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) signed in to law on March 27, 2020, provided that NOLs generated in a taxable year beginning in 2018, 2019, or 2020, may now be carried back five years and forward indefinitely. In addition, the limitation of NOL utilization up to 80% of taxable income limitation is temporarily removed, allowing NOLs to fully offset taxable income. Some of the state net operating losses follow the Federal Tax Cuts and Jobs Act and are carried over indefinitely, and others have various expiration dates. The NOL carry forward is subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of November 30, 2021. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses since inception, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of November 30, 2022, and 2021. The valuation allowance increased by approximately $0.3 million and $2.6 million for the fiscal years ended November 30, 2022 and 2021. The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 30, ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss carryforward ​ $ 11,579,000 ​ $ 11,438,000 Stocked based compensation ​ 7,171,000 ​ 6,889,000 License agreement ​ 70,000 ​ 183,000 Charitable contributions ​ 4,000 ​ 4,000 Other accrued tax expenses ​ 386,000 ​ ​ 329,000 Total deferred income tax assets ​ 19,210,000 ​ ​ 18,853,000 ​ ​ ​ ​ ​ ​ ​ Deferred tax liability: ​ ​ ​ ​ ​ ​ Convertible debt ​ $ (204,000) ​ $ (102,000) Total deferred income tax liability ​ ​ (204,000) ​ ​ (102,000) ​ ​ ​ ​ ​ ​ ​ Net deferred income tax assets ​ 19,006,000 ​ ​ 18,751,000 Valuation allowance ​ (19,006,000) ​ ​ (18,751,000) Deferred tax asset, net of allowance ​ $ — ​ $ — ​ A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2022 2021 Expected federal income tax benefit 21.0 % 21.0 % State taxes net of federal benefit 7.6 % 10.6 % Deferred tax true-up 0.0 % 0.0 % Gain/loss on conversion and extinguishment of debt 0.0 % 0.0 % Loss on settlement 0.0 % 0.0 % Change in fair value of embedded conversion option and related accretion of interest expense (3.9) % (1.0) % Meals and entertainment 0.0 % 0.0 % Non-U.S. operations (3.6) % (1.1) % Deferred tax rate change 0.2 % 0.2 % Change in valuation allowance (21.9) % (29.7) % Income taxes provision (benefit) — ​ — ​ ​ The Company’s major tax jurisdictions are the United States and New York. All of the Company’s tax years will remain open starting 2014 for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.

Subsequent Events

Subsequent Events	12 Months Ended
	Nov. 30, 2022
Subsequent Events
Subsequent Events	Note 13 - Subsequent Events On January 12 2023 the company entered into a promissory note with an accredited investor and current debt holder for $49,000. The note must be paid off in 10 installments. On February 13, 2023 the company entered into a 12 month convertible note for $62,387.00. On March 20 th On March 31 st

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2022
Summary of Significant Accounting Policies
Use of estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of warrants on the Company’s stock and the valuation of embedded derivatives within the Company’s convertible notes payable.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At November 30, 2022 and 2022, the Company had a cash balance that is insured by the FDIC limit. The Company had not experienced losses on these accounts.
Fair value of financial instruments	Fair Value of Financial Instruments ​ Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ​ ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the years ended November 30, 2022 and 2021. The respective carrying value of cash and accounts payable approximated their fair values as they are short term in nature.
Intangible Assets	Intangible Assets Intangible assets subject to amortization include acquired intellectual property for a marketable product acquired in November 2018. The intellectual property is being amortized over the estimated life remaining at the time of acquisition, which is 10 years. Intangible assets are monitored for potential impairment whenever events or circumstances indicate that the carrying amount may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. Management has assessed the economic life of the Company’s Metastron asset to be at least equal to its remaining use life of eight years. As such, management modelled the recoverability test using seven years of estimated future cash flows. Based on this projection, the $350,000 net carrying value of the Company’s Metastron asset is fully recoverable and therefore there was no impairment loss as of November 30, 2022 and 2011.
Debt Issuance Costs	Debt Issuance Costs Direct costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the accompanying Consolidated Balance Sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method.
Embedded Conversion Features	Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the Statement of Operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the Statement of Operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a binomial model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
Common Stock Warrants	Common Stock Warrants The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any warrants that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control), (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope exception. The Company assesses classification of its common stock warrants at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the criteria for equity or liability classification in the balance sheet. The warrants classified as liability are initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the consolidated statements of operations at each period end while such instruments remain outstanding.
Revenue Recognition	Revenue Recognition The core principle of Topic 606 (FASB ASC 606) is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The revenue recognition guidance contained in Topic 606, to follow the five-step revenue recognition model along with other guidance impacted by this standard: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transportation price; (4) allocate the transportation price; (5) recognize revenue when or as the entity satisfies a performance obligation. Previous practices were broadly consistent with this approach, and the company determined the amount of revenue based on the amount customer paid or promised to pay. The Company satisfies its performance obligation to deliver products when the customer has received the products, which is when title to the goods has transferred and the customer has control of the products. Payments from customers are generally received within 90 days of when the product is delivered. Because the Company’s agreements have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations.
Stock Based Compensation	Stock Based Compensation Effective December 1, 2018, the Company adopted ASU 2018-07, by which the accounting for share-based payments to non-employees and employees is substantially aligned. Non-employee share-based payment awards are measured at grant-date fair value of the equity instruments that the Company is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. There was no cumulative effect of the adoption of this standard. Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award and is recognized over the service period required for the award. Stock-based compensation expense is recognized in the consolidated financial statements based on the fair value of the awards granted. Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally represents the vesting period. The Company calculates the fair value of stock options using the Black-Scholes option-pricing model at grant date.
General and administrative expenses	General and administrative expenses The significant components of general and administrative expenses consist of stock-based compensation, investor relations fees, consulting, and professional fees.
Research and development	Research and development The Company expenses the cost of research and development as incurred. Research and development expenses include costs incurred in funding research and development activities, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made. For the year 2022, $3.6 million was converted from Licensing fees and Share awards expensed in Research and Development in recognition of shares received in Investment in an Associate - Mannin. We incurred a 500k loss between the value of shares received and the amount expended in Research and Development
Income Taxes	Income Taxes Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company applies a more-likely-than-not recognition threshold for all tax uncertainties, which only allows the recognition of those tax benefits that have a greater than fifty percent likelihood of being sustained upon examination by the taxing authorities. As of November 30, 2021 and 2020, the Company reviewed its tax positions and determined there were no outstanding, or retroactive tax positions with less than a 50% likelihood of being sustained upon examination by the taxing authorities, therefore this standard has not had a material effect on the Company. The Company’s policy for recording interest and penalties associated with audits is to record such expenses as a component of income tax expense. There were no amounts accrued for penalties or interest during the years ended November 30, 2022 and 2021. Management is currently unaware of any issues under review that could result in significant payments, accruals, or material deviations from its position.
Modification of Equity Classified Awards	Modification of Equity Classified Awards From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and on a straight-line basis over the same remaining amortization schedule as the unvested underlying equity awards. The classification of stock-based awards, including whether such instruments should be recorded as liabilities or as equity, is reassessed on the modification date.
Induced Conversion of Convertible Preferred Stock	Induced Conversion of Convertible Preferred Stock The Company accounts for gains or losses on extinguishment of equity-classified preferred stock as deemed dividends, to be included in the net loss per common stockholder used to calculate earnings per share. The difference between (1) the fair value of the consideration transferred to the holders of the preferred stock and (2) the carrying amount of the preferred stock (net of issuance costs) is subtracted from (or added to) net loss to arrive at net loss available to common stockholders in the calculation of earnings per share.
Sequencing Policy	Sequencing Policy The Company adopted a sequencing policy under ASC 815-40-35 (“ASC 815”) whereby in the event that reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain financial instruments with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, issuance of stock-based awards to the Company’s employees, non-employees or directors recognized under ASC 718 are not subject to the sequencing policy. Any modifications of awards (e.g., options or warrants) that remain subject to vesting, or any modifications of awards that continue to be held by active employees, are not subject to the sequencing policy. Modifications of vested awards held by non-employees are subject to the sequencing policy.
Recent Accounting Standards	Recent Accounting Standards In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity- classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company is still evaluating the impact of adoption the ASU 2021-04 on its condensed consolidated financial statements. ​
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards ​ In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company elected to early adopt this guidance on December 1, 2021, on a modified retrospective basis. The adoption resulted in approximately $291,000 decrease in additional paid in capital from the derecognition of the bifurcated equity component, $208,000 increase in debt from the derecognition of the discount associated with the bifurcated equity component and $83,000 decrease to the opening balance of accumulated deficit.

Loss per share (Tables)

Loss per share (Tables)	12 Months Ended
	Nov. 30, 2022
Loss per share
Schedule of potentially dilutive securities not considered in the computation of diluted net loss per share	​ ​ ​ ​ ​ ​ Potentially dilutive securities November 30, 2022 November 30, 2021 Series A convertible preferred stock 2,280,000 2,280,000 Series B convertible preferred stock ​ 8,457,000 ​ 11,429,000 Series C convertible preferred stock ​ 1,000,000 ​ — Common stock purchase warrants ​ 11,752,000 ​ 11,752,000 Stock Options ​ 4,450,000 ​ 4,450,000 Convertible Notes 86,360,000 4,898,000 Potentially dilutive securities 114,299,000 34,809,000

Intangible Asset Acquisition (T

Intangible Asset Acquisition (Tables)	12 Months Ended
	Nov. 30, 2022
Intangible Asset Acquisition
Schedule of amortization expense	​ ​ ​ ​ ​ Year ended November 30, ​ ​ 2023 ​ ​ 50,000 2024 ​ 50,000 2025 ​ 50,000 2026 ​ 50,000 2027 ​ 50,000 Thereafter ​ 50,000 ​ ​ $ 300,000

Debt (Tables)

Debt (Tables)	12 Months Ended
	Nov. 30, 2022
Debt
Schedule of convertible notes payable	The table below summarizes outstanding convertible notes as of November 30, 2022, and 2021 (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ November 30, 2022 November 30, 2021 Convertible Notes Payable: ​ ​ Principal value of 2021 Debentures ​ $ 2,408,000 ​ $ 3,506,000 Fair value of bifurcated contingent put option ​ 1,099,000 ​ 867,000 Debt discount ​ (70,000) ​ (1,320,000) 2021 Convertible notes payable, net ​ 3,437,000 ​ ​ 3,053,000 Principal value of 2022 Debentures ​ ​ 560,000 ​ ​ — Fair value of bifurcated contingent put option ​ ​ 333,000 ​ ​ — Debt discount ​ ​ (305,000) ​ ​ — 2022 Convertible notes payable, net ​ ​ 588,000 ​ ​ 3,053,000 Cash advances ​ ​ 85,000 ​ ​ — Total carrying value of convertible notes payable ​ $ 4,110,000 ​ $ 3,053,000 ​
Schedule of fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ November 30, 2022 November 30, 2021 ​ Strike price ​ $ 0.55 ​ $ 0.71 ​ Terms (years) ​ ​ 0.3 ​ ​ 0.8 ​ Volatility ​ ​ 200 % ​ 71 % Risk-free rate ​ ​ 2.9 % ​ 0.2 % Dividend yield ​ ​ 0 % ​ 0 % ​
Schedule of discounted maximum redemption premium	​ ​ ​ ​ ​ Balance December 1, 2020 $ — Additional derivative liability ​ 603,000 Debt extinguishment ​ (40,000) Change in fair value ​ ​ 304,000 Balance November 30, 2021 ​ $ 867,000 Issuance of convertible notes ​ ​ 271,000 Debt extinguishment ​ ​ (425,000) Change in fair value ​ 721,000 Balance November 30, 2022 ​ $ 1,434,000 ​
Schedule of interest expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years ended ​ November 30, 2022 November 30, 2021 Interest expense based on the coupon interest rate of the outstanding debt ​ $ 252,000 ​ $ 96,000 Accretion of debt discount ​ 1,073,000 ​ 408,000 Other ​ 60,000 ​ 3,000 Total interest expense ​ $ 1,385,000 ​ $ 507,000
July 2021 Debenture | Warrants
Debt
Schedule of fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ ​ July 1, 2022 ​ Strike price ​ $ 0.05 Terms (years) ​ 1.0 Volatility ​ 138 % Risk-free rate ​ ​ 2.8 % Dividend yield ​ 0 % Probability factor ​ 20 %
September 2021 Debenture
Debt
Schedule of fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ September 29, 2021 Strike price ​ $ 0.50 ​ Terms (years) ​ ​ 1.0 ​ Volatility ​ ​ 66 % Risk-free rate ​ ​ 0.1 % Dividend yield ​ ​ — % ​
July 2022 Debenture
Debt
Schedule of fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ ​ July 1, 2022 ​ Strike price ​ $ 0.05 Terms (years) ​ 1.0 Volatility ​ 138 % Risk-free rate ​ ​ 2.8 % Dividend yield ​ 0 % Probability factor ​ 20 % ​
August 2022 Debenture
Debt
Schedule of fair value measurement inputs and valuation techniques	​ ​ ​ ​ ​ ​ ​ ​ August 10, 2022 ​ Strike price ​ $ 0.04 Terms (years) ​ 0.5 Volatility ​ 200 % Risk-free rate ​ ​ 3.1 % Dividend yield ​ 0 % ​

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Nov. 30, 2022
Commitments and Contingencies
Schedule of Consolidated Statements of Operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2022 2021 Rent expense ​ $ 30,000 ​ $ 30,000 ​

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Nov. 30, 2022
Related Party Transactions
Schedule of general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years ended ​ November 30, 2022 November 30, 2021 Consulting and legal expenses ​ $ 308,000 ​ $ 420,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Nov. 30, 2022
Stockholders' Deficit
Schedule original issue price and the liquidation value per share for each class of preferred stock	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Original Issue Price ​ Liquidation Value ​ Per Share Per Share Series A Preferred Share ​ $ 10.00 ​ $ 10.20 Series B Preferred Share ​ $ 10.00 ​ $ 10.25 Series C Preferred Share ​ $ 0.05 ​ $ — ​

Warrants and Options (Tables)

Warrants and Options (Tables)	12 Months Ended
	Nov. 30, 2022
Warrants and Options
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ February 22, 2022 ​ Strike price ​ $ 0.50 ​ Terms (years) ​ 3.0 ​ Volatility ​ 126 % Risk-free rate ​ 1.7 % Dividend yield ​ 0.0 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 0.65 ​ $ 2.33 ​ Term (years) ​ ​ 2.5 ​ 2.1 ​ Volatility ​ ​ 135 % 127 % Risk-free rate ​ ​ 1.0 % ​ 1.0 % Dividend yield ​ ​ 0.0 % 0.0 % ​
Common stock purchase warrants [Member]
Warrants and Options
Summary of warrants	The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at November 30, 2022 and 2021 and the changes during the period then ended (warrants amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Warrants Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 11,752,000 ​ $ 1.97 2.60 ​ $ — Issued 400,000 ​ ​ 0.50 2.23 ​ ​ — Forfeited/expired ​ (932,000) ​ ​ — ​ — ​ ​ — Outstanding and exercisable at November 30, 2022 ​ 11,220,000 ​ $ 1.01 ​ 3.8 ​ $ — ​ Grant date fair value of all outstanding warrants was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ ​ 2022 2021 ​ Strike price ​ $ 1.25 ​ $ 1.25 ​ Term (years) ​ 5.0 ​ ​ 5.0 ​ Volatility ​ 114 % ​ 114 % Risk-free rate ​ 0.4 % ​ 0.8 % Dividend yield ​ 0.0 % ​ 0.0 % ​ Modification date fair value of all outstanding warrants was based on the following key inputs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ After Modification Before Modification Strike price ​ $ 1.77 ​ $ 2.51 ​ Term (years) ​ ​ 3.5 ​ 0.8 ​ Volatility ​ ​ 123 % 77 % Risk-free rate ​ ​ 0.5 % ​ 0.4 % Dividend yield ​ ​ 0.0 % 0.0 % ​
Stock Options [Member]
Warrants and Options
Schedule of fair value outstanding warrants and options issued to non-employees for services	​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2021 Strike price ​ $ 0.45 ​ Term (years) ​ 5.0 ​ Volatility ​ 111 % Risk-free rate ​ 1.2 % Dividend yield ​ 0.0 % ​
Schedule of options issued for services	The following represents a summary of all outstanding options to purchase the Company’s common stock at November 30, 2022 and 2021 and the changes during the period then ended (options amount and intrinsic value are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ Remaining Contractual ​ ​ ​ ​ Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2021 4,450,000 ​ $ 1.13 4.0 ​ $ 1,000 Issued 3,000,000 ​ ​ 0.10 5.0 ​ ​ — Forfeited/expired ​ — ​ ​ — ​ — ​ ​ — Outstanding at November 30, 2022 ​ 7,450,000 ​ $ 0.10 ​ 6.5 ​ $ — Exercisable at November 30, 2022 ​ 5,200,000 ​ $ 0.10 ​ 7.5 ​ $ — ​

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Nov. 30, 2022
Income Taxes
Schedule of deferred tax asset, net of allowance	The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following (amounts are rounded to nearest thousand): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of November 30, ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss carryforward ​ $ 11,579,000 ​ $ 11,438,000 Stocked based compensation ​ 7,171,000 ​ 6,889,000 License agreement ​ 70,000 ​ 183,000 Charitable contributions ​ 4,000 ​ 4,000 Other accrued tax expenses ​ 386,000 ​ ​ 329,000 Total deferred income tax assets ​ 19,210,000 ​ ​ 18,853,000 ​ ​ ​ ​ ​ ​ ​ Deferred tax liability: ​ ​ ​ ​ ​ ​ Convertible debt ​ $ (204,000) ​ $ (102,000) Total deferred income tax liability ​ ​ (204,000) ​ ​ (102,000) ​ ​ ​ ​ ​ ​ ​ Net deferred income tax assets ​ 19,006,000 ​ ​ 18,751,000 Valuation allowance ​ (19,006,000) ​ ​ (18,751,000) Deferred tax asset, net of allowance ​ $ — ​ $ — ​
Schedule of reconciliation of statutory income tax rates and Company's effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ For the year ended November 30, ​ 2022 2021 Expected federal income tax benefit 21.0 % 21.0 % State taxes net of federal benefit 7.6 % 10.6 % Deferred tax true-up 0.0 % 0.0 % Gain/loss on conversion and extinguishment of debt 0.0 % 0.0 % Loss on settlement 0.0 % 0.0 % Change in fair value of embedded conversion option and related accretion of interest expense (3.9) % (1.0) % Meals and entertainment 0.0 % 0.0 % Non-U.S. operations (3.6) % (1.1) % Deferred tax rate change 0.2 % 0.2 % Change in valuation allowance (21.9) % (29.7) % Income taxes provision (benefit) — ​ — ​ ​

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Net carrying value	$ 300,000	$ 350,000
Remaining estimated life	7 years
Decrease in additional paid in capital	$ 291,000
Increase in debt from derecognition of discount associated with bifurcated equity component	208,000
Decrease to opening balance of accumulated deficit	83,000
Amount converted	3,600,000
Loss incurred	500,000
Mannin Agreement [Member]
Amount converted	3,600,000
Loss incurred	$ 500,000
Intellectual Property [Member]
Remaining estimated life	10 years
Metastron Asset
Net carrying value		350,000
Remaining estimated life	8 years
Impairment loss	$ 0	$ 0

Loss per share (Details)

Loss per share (Details) - shares	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	114,299,000	34,809,000
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	2,280,000	2,280,000
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	8,457,000	11,429,000
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	1,000,000
Common stock purchase warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	11,752,000	11,752,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	4,450,000	4,450,000
Convertible Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities	86,360,000	4,898,000

Intangible Asset Acquisition -

Intangible Asset Acquisition - Amortization expense (Details) - USD ($)	Nov. 30, 2022	Nov. 30, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Total	$ 300,000	$ 350,000
GE Healthcare Limited | Intellectual Property [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
2023	50,000
2024	50,000
2025	50,000
2026	50,000
2027	50,000
Thereafter	50,000
Total	$ 300,000

Intangible Asset Acquisition _2

Intangible Asset Acquisition - Additional information (Details) - USD ($)		12 Months Ended
	Nov. 23, 2018	Nov. 30, 2022	Nov. 30, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization term	10 years
Amortization expense		$ 50,000	$ 50,000
GE Healthcare Limited | Intellectual Property [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Upfront payments	$ 500,000

Investment (Details)

Investment (Details) - Mannin $ in Thousands	12 Months Ended
	Nov. 30, 2022 USD ($)
Investment
Expenses from investment	$ 3,600
Loss between value of shares received and amount expended in Research and Development	$ 500

Debt (Details)

Debt (Details) - USD ($)	Nov. 30, 2022	Nov. 30, 2021
Convertible Notes Payable:
Cash advances	$ 85,000
Total carrying value of convertible notes payable	4,110,000	$ 3,053,000
2021 Debentures
Convertible Notes Payable:
Principal value	2,408,000	3,506,000
Fair value of bifurcated contingent put option	1,099,000	867,000
Debt discount	(70,000)	(1,320,000)
Convertible notes payable, net	3,437,000	3,053,000
2022 Debentures
Convertible Notes Payable:
Principal value	560,000
Fair value of bifurcated contingent put option	333,000
Debt discount	(305,000)
Convertible notes payable, net	$ 588,000	$ 3,053,000

Debt - Fair value measurement i

Debt - Fair value measurement inputs (Details)	Aug. 10, 2022 Y $ / shares	Jul. 01, 2022 $ / shares Y	Sep. 29, 2021 Y $ / shares
Strike price
Debt
Input | $ / shares	0.04	0.05	0.50
Terms (years)
Debt
Input | Y	0.5	1	1
Volatility
Debt
Input	2	1.38	0.66
Risk-free rate
Debt
Input	0.031	0.028	0.001
Dividend yield
Debt
Input	0	0
Probability factor
Debt
Input		0.20
Warrants | Strike price
Debt
Input | $ / shares		0.05
Warrants | Terms (years)
Debt
Input | Y		1
Warrants | Volatility
Debt
Input		1.38
Warrants | Risk-free rate
Debt
Input		0.028
Warrants | Dividend yield
Debt
Input		0
Warrants | Probability factor
Debt
Input		0.20

Debt - Fair value of the contin

Debt - Fair value of the contingent (Details) - $ / shares	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Debt
Strike price	$ 0.55	$ 0.71
Terms (years)	3 months 18 days	9 months 18 days
Volatility	200%	71%
Risk-free rate	2.90%	0.20%
Dividend yield	0%	0%

Debt - Changes in Level 3 liabi

Debt - Changes in Level 3 liabilities measured at fair value (Details) - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Debt
Balance at beginning	$ 867,000
Issuance of convertible notes	271,000
Additional derivative liability		$ 603,000
Debt extinguishment	(425,000)	(40,000)
Change in fair value	721,000	304,000
Balance at ending	$ 1,434,000	$ 867,000

Debt - Additional information (

Debt - Additional information (Details)														3 Months Ended			12 Months Ended
	Nov. 22, 2022 USD ($)	Oct. 18, 2022 USD ($)	Sep. 15, 2022 USD ($)	Aug. 10, 2022 USD ($) $ / shares shares	Jul. 26, 2022 item USD ($) $ / shares	Jul. 01, 2022 USD ($) item	Apr. 08, 2022 USD ($) shares	Jan. 21, 2022 USD ($) $ / shares shares	Dec. 15, 2021 USD ($)	Sep. 29, 2021 USD ($) D $ / shares	Jul. 26, 2021 USD ($) item D $ / shares shares	Jul. 22, 2021 USD ($) $ / shares	Feb. 12, 2021 USD ($) D $ / shares	Aug. 31, 2022 USD ($)	May 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Nov. 30, 2022 USD ($) shares	Nov. 30, 2021 USD ($) shares
Debt
Proceeds received from issuance of convertible notes, net																	$ 652,731	$ 3,458,900
Conversion price | $ / shares								$ 0.50
Shares issued, conversion of debt | shares								1,055,000									21,025,054	945,631
Amount of debt converted								$ 500,000									$ 1,246,000
Embedded derivative liability																	365,000
Loss on debt extinguishment																	(384,311)	$ (40,910)
Warrants exercisable term															5 years
Increase in outstanding principal balance									$ 241,875
2020 Debentures
Debt
Loss on debt extinguishment												$ 15,000
Floor price of debentures | $ / shares												$ 0.50
2021 Debentures
Debt
Fair value of bifurcated contingent put option																	$ 1,099,000	$ 867,000
February 2021 Debenture
Debt
Issue of debentures, amount													$ 500,000
Interest rate (as percent)													5.50%
Aggregate fair value of the conversion option on the issuance date recognized as additional debt discount													$ 28,000
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced													93%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | D													4
Number of consecutive trading days | D													10
Commitment fee (as percent)													2%
Embedded derivative liability								$ 95,000
Loss on debt extinguishment														$ 232,000	$ 232,000	$ 232,000
February 2021 Debenture | Maximum
Debt
Conversion price | $ / shares													$ 1.15
February 2021 Debenture | Minimum
Debt
Conversion price | $ / shares													$ 1
July 2021 Debenture
Debt
Issue of debentures, amount											$ 806,250
Interest rate (as percent)											10%
Aggregate fair value of the conversion option on the issuance date recognized as additional debt discount											$ 209,000
Default interest rate											15%
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced					85%						85%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | item					4						4
Number of consecutive trading days					20						20
Shares issued, conversion of debt | shares																	3,633,862
Amount of debt converted																	$ 413,000
Embedded derivative liability																	159,000
Loss on debt extinguishment																	152,000
Number of warrants issued | shares											645,000
Total purchase price											$ 750,000
External counsel legal costs											$ 18,750
Floor price of debentures | $ / shares					$ 0.35
Readjusted initial floor price | $ / shares					0.10
Minimum price of VWAP to be satisfied for adjustment for at least 10 days | $ / shares					$ 0.35
Number of days at least VWAP should be $0.35					10 days
July 2021 Debenture | Maximum
Debt
Conversion price | $ / shares					$ 1						$ 1
July 2021 Debenture | Warrants
Debt
Total purchase price											$ 253,000
Exercise price | $ / shares											$ 1.25
Warrants exercisable term											5 years
September 2021 Debenture
Debt
Original issue discount										$ 185,000
Issuance costs										$ 15,000							$ 247,350
Interest rate (as percent)										6%
Conversion price | $ / shares										$ 1
Aggregate fair value of the conversion option on the issuance date recognized as additional debt discount										$ 278,000
Percentage of average of the four lowest daily VWAPs on basis of which conversion price is reduced										85%
Number of lowest daily VWAPs during the 10 consecutive trading days on basis of which conversion price is reduced | D										4
Number of consecutive trading days										10
Shares issued, conversion of debt | shares																	21,025,054
Amount of debt converted																	$ 305,000
Embedded derivative liability																	$ 146,000
Carrying value of convertible notes										$ 2,200,000
Debt conversion term										12 months
Percent of prepayment within first 60 days of issuance										105%
Percent of prepayment from 61-120 days after issuance										112%
Percent of prepayment from 121 to 180 days after issuance										124%
Conversion price after six months | $ / shares										$ 0.50
Number of prior trading days in conversion price | D										20
Stock issued during period, shares, commitment fee | shares							245,000
Stock issued during period, value, commitment fee							$ 177,000
July 2022 Debenture
Debt
Issue of debentures, amount						$ 119,888
Original issue discount						16,888
Due diligence fee retained						1,250
Issuance costs						$ 3,000
Interest rate (as percent)						10%
Threshold period after which the note can be converted						180 days
Conversion price percentage						80%
Number of lowest trading price considered | item						3
Look back period						10 days
Fair value of bifurcated contingent put option						$ 104,000
Net proceeds						100,000
Loss on issuance of convertible note						$ 4,000
August 2022 Debenture
Debt
Issue of debentures, amount				$ 275,000
Interest rate (as percent)				10%
Proceeds received from issuance of convertible notes, net				$ 250,000
Period after the 6-month anniversary, the Lender has the exclusive right to elect conversion				30 days
Conversion price | $ / shares				$ 0.035
Aggregate fair value of the conversion option on the issuance date recognized as additional debt discount				$ 23,000
Commitment shares agreed to be issued | shares				300,000
Threshold number of business days within which commitment shares are to be issued				10
Amount of commitment shares valued at the effective date fair value recognized as additional debt discount				$ 11,000
September 2022 Debenture
Debt
Issue of debentures, amount			$ 102,637
Interest rate (as percent)			6%
Default interest rate			22%
Percent of prepayment within first 60 days of issuance			120%
Percent of prepayment from 61 to 180 days after issuance			130%
October 2022 Debenture
Debt
Issue of debentures, amount		$ 63,250
Interest rate (as percent)		6%
Default interest rate		22%
Percent of prepayment within first 60 days of issuance		120%
Percent of prepayment from 61 to 180 days after issuance		130%
November 2022 Debenture
Debt
Issue of debentures, amount	$ 62,387
Interest rate (as percent)	6%
Default interest rate	22%
Percent of prepayment within first 60 days of issuance	120%
Percent of prepayment from 61 to 180 days after issuance	130%

Debt - Interest expense (Detail

Debt - Interest expense (Details) - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Debt
Interest expense based on the coupon interest rate of the outstanding debt	$ 252,000	$ 96,000
Accretion of debt discount	1,073,000	408,000
Other	60,000	3,000
Total interest expense	$ 1,385,000	$ 507,000

Commitments and Contingencies_2

Commitments and Contingencies (Details)

1 Months Ended

12 Months Ended

Aug. 24, 2022 USD ($)

Aug. 15, 2022 USD ($)

Jul. 19, 2022 USD ($)

Jul. 12, 2022 USD ($)

Mar. 11, 2022 USD ($)

Jun. 30, 2021 USD ($)

May 05, 2021 USD ($) shares

Feb. 26, 2021 shares

Dec. 31, 2020 USD ($)

Sep. 01, 2020 USD ($)

Jun. 15, 2020 USD ($)

Apr. 09, 2019 shares

Mar. 09, 2019 USD ($)

Dec. 31, 2016 USD ($)

Oct. 29, 2015

Nov. 30, 2022 USD ($)

Nov. 30, 2021 USD ($)

Commitments and Contingencies

Rent expense

$ 30,000

$ 30,000

Issuance of common stock and warrants for cash net of offering cost , Shares | shares

100,000

Aggregate Cash payable

125,378

1,073,841

Amount converted from Licensing fees and Share awards expensed

3,600,000

Loss incurred between shares received and amount expended in research and development

500,000

Aedesius

Commitments and Contingencies

Number of maximum units to be sold | shares

16,000,000

Aggregate price from sale of units

$ 20,000,000

WSI PBG, LLC

Commitments and Contingencies

Damages sought

$ 196,216

Judgement obtained

$ 203,784

Activus Group

Commitments and Contingencies

Damages sought

$ 129,600

Diligent Health Solutions, LLC

Commitments and Contingencies

Damages sought

$ 106,000

Judgement obtained

$ 111,000

Advisory Agreements | EF Hutton

Commitments and Contingencies

Bridge or other private offering value

$ 2,000,000

External counsel legal costs

15,000

Legal fees outstanding

0

Advisory Agreements | EF Hutton | Maximum

Commitments and Contingencies

External counsel legal costs

$ 50,000

Lease agreement

Commitments and Contingencies

Lease cost per annum

$ 30,000

Renewal term (in years)

3 years

License agreement

Commitments and Contingencies

Aggregate Cash payable

$ 100,000

$ 1,100,000

License agreement | Mannin | Intellectual Property

Commitments and Contingencies

License agreement (in years)

4 years

Mannin agreement

Commitments and Contingencies

Issuance of common stock and warrants for cash net of offering cost , Shares | shares

100,000

Aggregate Cash payable

$ 1,500,000

Installment paid under license agreement

$ 700,000

Outstanding payables

$ 400,000

$ 400,000

Issuance of common shares for debt conversion

$ 750,000

Percentage of rights held on revenue

100

Increase in funds limit

$ 2,000,000

Amount converted from Licensing fees and Share awards expensed

3,600,000

Loss incurred between shares received and amount expended in research and development

$ 500,000

Washington university

Commitments and Contingencies

Initial fee

$ 88,000

Washington university | Minimum

Commitments and Contingencies

Annual maintenance fees

15,000

Washington university | Maximum

Commitments and Contingencies

Annual maintenance fees

$ 75,000

Related Party Transactions (Det

Related Party Transactions (Details)			12 Months Ended
	Aug. 31, 2021 USD ($)	Feb. 01, 2021 USD ($) shares	Nov. 30, 2022 USD ($) $ / shares	Nov. 30, 2021 USD ($) $ / shares	May 29, 2022 $ / shares shares	Apr. 16, 2021 USD ($) item
Related Party Transactions
Consulting and legal expenses			$ 308,000	$ 420,000
Nominal value per share | $ / shares			$ 0.001	$ 0.001
Fair Value		$ 35,000
Repayment of notes payable - related parties				$ 30,000
Management personnel
Related Party Transactions
Repayment of notes payable - related parties	$ 30,000
Unsecured promissory notes agreement | Management personnel
Related Party Transactions
Number of unsecured promissory notes agreements entered | item						2
Maximum borrowing capacity of related party promissory note						$ 30,000
Interest rate (as percent)						5%
Mr Rosenstadt
Related Party Transactions
Shares issued | shares		35,000			250,000
Nominal value per share | $ / shares					$ 10
Mr Corin
Related Party Transactions
Shares issued | shares					200,000
Nominal value per share | $ / shares					$ 10

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)						12 Months Ended
	Feb. 14, 2022	Jan. 21, 2022	May 20, 2021	Feb. 28, 2021	Feb. 26, 2021	Nov. 30, 2022	Nov. 30, 2021	Feb. 22, 2022
Stockholders' Deficit
Common stock, shares authorized						250,000,000	250,000,000
Common stock, par value						$ 0.001	$ 0.001
Number of preferred shares authorized						100,000,000	100,000,000
Preferred stock, par value						$ 0.001	$ 0.001
Issuance of common stock and warrants for cash net of offering cost , Shares					100,000
Shares issued, conversion of debt		1,055,000				21,025,054	945,631
Debt conversion value						$ 2,077,386	$ 703,614
Proceeds received for issuance of common stock					$ 100,000
Share based compensation for services (in shares)						1,880,941
Share based compensation for services						$ 392,002	2,338,580
Amount of debt converted		$ 500,000				1,246,000
Embedded derivative liability						365,000
Unamortized debt discount reversed						118,000
Loss on debt extinguishment						$ (384,311)	$ (40,910)
Series A Preferred Stock
Stockholders' Deficit
Exercise price per share						$ 10
Liquidation Value Per Share						$ 10.20
Issuance of common stock and warrants for cash net of offering cost , Shares						5,497,333
Series B Preferred Stock
Stockholders' Deficit
Exercise price per share						$ 10
Liquidation Value Per Share						$ 10.25
Issuance of common stock and warrants for cash net of offering cost , Shares						5,497,333
Shares issued for conversion				1,245,089		25,655,298
Issuance of common shares for preferred stock conversion				103,000		25,655,298
Series C Preferred Stock
Stockholders' Deficit
Exercise price per share						$ 0.05
Issuance of common stock and warrants for cash net of offering cost , Shares						1,000,000
Common Stock
Stockholders' Deficit
Shares issued for conversion						21,025,054	945,631
Share based compensation for services (in shares)						1,880,941	758,636
Share based compensation for services						$ 1,881	$ 759
Securities purchase agreement | Common Stock
Stockholders' Deficit
Sale of units	400,000		1,213,333
Exercise price			$ 0.80
Sale price, per unit	$ 0.25		$ 0.75
Dividends common stock, amount	$ 100,000		$ 900,000
Exercise price								$ 0.28
common stock exercise price	$ 0.50		$ 1.25
General and Administrative Expense
Stockholders' Deficit
Share based compensation for services (in shares)							758,636
Share based compensation for services							$ 700,000

Stockholders' Deficit - Preferr

Stockholders' Deficit - Preferred shares (Details) - USD ($)		12 Months Ended
	Feb. 26, 2021	Nov. 30, 2022	Nov. 30, 2021	Feb. 28, 2021
Stockholders' Deficit
Issuance common stock for dividend payment on series A and series B preferred stock		$ 500,000	$ 500,000
Deemed dividend for induced conversion of convertible preferred stock		$ 968,160
Issuance of Series A and Series B preferred stock for cash (Shares)	100,000
Accumulated dividend on preferred stock			$ 100,000
Series A Preferred Stock
Stockholders' Deficit
Original Issue Price Per Share		$ 10
Liquidation Value Per Share		$ 10.20
Issuance of Series A and Series B preferred stock for cash (Shares)		5,497,333
Series B Preferred Stock
Stockholders' Deficit
Original Issue Price Per Share		$ 10
Liquidation Value Per Share		$ 10.25
Issuance of common shares for preferred stock conversion		25,655,298		103,000
Number of shares converted		104,000
Issuance of Series A and Series B preferred stock for cash (Shares)		5,497,333
Series C Preferred Stock
Stockholders' Deficit
Original Issue Price Per Share		$ 0.05
Issuance of Series A and Series B preferred stock for cash (Shares)		1,000,000
Preferred stock
Stockholders' Deficit
Deemed dividend for induced conversion of convertible preferred stock		$ 1
Accumulated dividend on preferred stock		$ 500,000
Common Stock
Stockholders' Deficit
Issuance common stock for dividend payment on series A and series B preferred stock		5,497,333	533,610
Officers And Directors
Stockholders' Deficit
Settlement of amount due		$ 50,000

Stockholders' Deficit - Common

Stockholders' Deficit - Common shares (Details) - USD ($)							12 Months Ended
	Feb. 14, 2022	Jan. 21, 2022	May 20, 2021	Feb. 28, 2021	Feb. 26, 2021	Feb. 14, 2021	Nov. 30, 2022	Nov. 30, 2021
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services (in shares)							1,880,941
Share based compensation for services							$ 392,002	$ 2,338,580
Shares issued, conversion of debt		1,055,000					21,025,054	945,631
Amount of debt converted		$ 500,000					$ 1,246,000
Embedded derivative liability							365,000
Unamortized debt discount reversed							118,000
Loss on debt extinguishment							(384,311)	$ (40,910)
Issuance of common stock and warrants for cash net of offering cost , Shares					100,000
Proceeds received for issuance of common stock					$ 100,000
Proceeds from sale of securities							100,030	910,000
Debt conversion value							$ 2,077,386	$ 703,614
Common Stock
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services (in shares)							1,880,941	758,636
Share based compensation for services							$ 1,881	$ 759
Shares issued for conversion							21,025,054	945,631
Issuance of common stock and warrants for cash (in shares)							400,000	1,213,333
Proceeds from sale of securities							$ 400	$ 1,213
Issuance of common stock to convert Series B preferred stock (in shares)							25,655,298	1,245,089
Common Stock | Securities purchase agreement
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Sale of units	400,000		1,213,333
Sale price, per unit	$ 0.25		$ 0.75
Dividends common stock, amount	$ 100,000		$ 900,000
Number of common stock shares in unit			1			1
Number of warrants issued per unit	1		1
Number of shares issuable per warrants	1
common stock exercise price	$ 0.50		$ 1.25
Exercise price			$ 0.80
Common Stock | Stock Options and Restricted Stock
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services							$ 240,000
Series B Preferred Stock
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Shares issued for conversion				1,245,089			25,655,298
Number of shares converted							104,000
Issuance of common stock and warrants for cash net of offering cost , Shares							5,497,333
Original Issue Price Per Share							$ 10
Issuance of common shares for preferred stock conversion				103,000			25,655,298
Common Stock
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services							$ 88,000
General and Administrative Expense
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services (in shares)								758,636
Share based compensation for services								$ 700,000
General and Administrative Expense | Common Stock | Stock Options and Restricted Stock
Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]
Share based compensation for services							$ 240,000

Stockholders' Deficit - Financi

Stockholders' Deficit - Financing agreements (Details) - USD ($)			12 Months Ended
	Jan. 21, 2022	Feb. 26, 2021	Nov. 30, 2022	Nov. 30, 2021	Nov. 22, 2022	Oct. 18, 2022	Sep. 15, 2022
Stockholders' Deficit
Shares issued, conversion of debt	1,055,000		21,025,054	945,631
Issuance of common stock to convert notes payable and accrued interest			$ 2,077,386	$ 703,614
Issuance of Series A and Series B preferred stock for cash (Shares)		100,000
September 2022 Debenture
Stockholders' Deficit
Principal value							$ 102,637
October 2022 Debenture
Stockholders' Deficit
Principal value						$ 63,250
November 2022 Debenture
Stockholders' Deficit
Principal value					$ 62,387

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - USD ($)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Weighted Average Remaining Contractual Life (years)
Outstanding		4 years
Issued	5 years
Forfeited/expired	0 years
Common stock purchase warrants
Warrants
Issued	400,000
Forfeited/expired	(932,000)
Ending balance	11,220,000	11,752,000
Weighted Average Exercise Price
Beginning balance	$ 1.97
Issued	0.50
Ending balance	$ 1.01	$ 1.97
Weighted Average Remaining Contractual Life (years)
Issued	2 years 2 months 23 days
Forfeited/expired	0 years
Ending balance	3 years 9 months 18 days	2 years 7 months 6 days
Intrinsic Value
Forfeited/expired		$ 0
Stock Options
Warrants
Issued	3,000,000
Ending balance	7,450,000	4,450,000
Exercisable at November 30, 2022	5,200,000
Weighted Average Exercise Price
Beginning balance	$ 1.13
Issued	0.10
Ending balance	$ 0.10	$ 1.13
Exercisable at November 30, 2022	0.10
Weighted Average Remaining Contractual Life (years)
Ending balance	6 years 6 months
Exercisable at November 30, 2022	7 years 6 months
Intrinsic Value
Outstanding		$ 1,000

Warrants and Options - Fair val

Warrants and Options - Fair value of warrants and modification of warrants (Details) - $ / shares		3 Months Ended		12 Months Ended
	Feb. 22, 2022	Aug. 31, 2022	May 31, 2022	Nov. 30, 2022	Nov. 30, 2021
Warrants and Options
Strike price				$ 0.55	$ 0.71
Term (years)				3 months 18 days	9 months 18 days
Volatility				200%	71%
Risk-free rate				2.90%	0.20%
Dividend yield				0%	0%
After Modification
Warrants and Options
Strike price				$ 1.77
Term (years)				3 years 6 months
Volatility				123%
Risk-free rate				0.50%
Dividend yield				0%
Before Modification
Warrants and Options
Strike price				$ 2.51
Term (years)				9 months 18 days
Volatility				77%
Risk-free rate				0.40%
Dividend yield				0%
Common stock purchase warrants
Warrants and Options
Strike price	$ 0.50			$ 1.25	$ 1.25
Term (years)	3 years			5 years	5 years
Volatility	126%			114%	114%
Risk-free rate	1.70%			0.40%	0.80%
Dividend yield	0%			0%	0%
Stock Options
Warrants and Options
Strike price					$ 0.45
Term (years)					5 years
Volatility					111%
Risk-free rate					1.20%
Dividend yield					0%
Stock Options | Minimum
Warrants and Options
Risk-free rate				1%	1%
Stock Options | After Modification
Warrants and Options
Strike price		$ 0.10	$ 0.51	$ 0.65
Term (years)		2 years 8 months 12 days	6 years 10 months 24 days	2 years 6 months
Volatility		151%	118%	135%
Risk-free rate		3.50%	2.70%	1%
Dividend yield		0%	0%	0%
Stock Options | Before Modification
Warrants and Options
Strike price		$ 0.50	$ 1.76	$ 2.33
Term (years)		2 years 8 months 12 days	2 years 1 month 6 days		2 years 1 month 6 days
Volatility		151%	128%	127%
Risk-free rate		3.50%	2.20%	1%
Dividend yield		0%	0%		0%

Warrants and Options - Addition

Warrants and Options - Additional information (Details) - USD ($)				1 Months Ended		2 Months Ended	3 Months Ended		12 Months Ended
	Feb. 01, 2022	Nov. 30, 2021	May 01, 2020	Aug. 31, 2022	Feb. 28, 2022	May 31, 2022	Aug. 31, 2022	May 31, 2022	Nov. 30, 2022	Nov. 30, 2021	Feb. 12, 2020
Warrants and Options
Number of modified warrants	245,625	17,000	20,000		5,461,432
Warrants exercisable term						5 years		5 years
Share based compensation related to warrants modification									$ 277,897
General and administrative expenses									3,311,249	$ 6,263,475
Research and development expenses									125,378	1,073,841
Unrecognized stock-based compensation									$ 210,000
Stock Options [Member]
Warrants and Options
Stock options granted									3,000,000
Exercise price									$ 0.10
After Modification
Warrants and Options
Number of modified warrants						4,765,807
Exercise price of warrant											$ 0.65
Share based compensation related to warrants modification								$ 261,000
After Modification | Minimum
Warrants and Options
Exercise price of warrant						$ 0.50		$ 0.50
After Modification | Maximum
Warrants and Options
Exercise price of warrant						$ 0.65		$ 0.65
After Modification | Stock options, after modification [Member]
Warrants and Options
Number of modified warrants				3,608,641
Exercise price of warrant				$ 0.10			$ 0.10
Share based compensation related to warrants modification							$ 22,000
Options And Warrants
Warrants and Options
Research and development expenses										$ 2,300,000

Income Taxes - Additional infor

Income Taxes - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Income Taxes
Operating loss carryforwards	$ 33
Amount of net operating loss carryforward that begins to expire in 2034	10
Increase in valuation allowance	$ 0.3	$ 2.6
Limitation of NOL utilization of taxable income	80%

Income Taxes - Tax effects of t

Income Taxes - Tax effects of temporary differences and carry forwards (Details) - USD ($)	Nov. 30, 2022	Nov. 30, 2021
Deferred tax assets:
Net operating loss carryforward	$ 11,579,000	$ 11,438,000
Stocked based compensation	7,171,000	6,889,000
License agreement	70,000	183,000
Charitable contributions	4,000	4,000
Other accrued tax expenses	386,000	329,000
Total deferred income tax assets	19,210,000	18,853,000
Deferred tax liability:
Convertible debt	(204,000)	(102,000)
Total deferred income tax liability	(204,000)	(102,000)
Net deferred income tax assets	19,006,000	18,751,000
Valuation allowance	(19,006,000)	(18,751,000)
Deferred tax asset, net of allowance	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of statutory income tax rate (Details)	12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Income Taxes
Expected federal income tax benefit	21%	21%
State taxes net of federal benefit	7.60%	10.60%
Deferred tax true-up	0%	0%
Gain/loss on conversion and extinguishment of debt	0%	0%
Loss on settlement	0%	0%
Change in fair value of embedded conversion option and related accretion of interest expense	(3.90%)	(1.00%)
Meals and entertainment	0%	0%
Non-U.S. operations	(3.60%)	(1.10%)
Deferred tax rate change	0.20%	0.20%
Change in valuation allowance	(21.90%)	(29.70%)
Income taxes provision (benefit)	0%	0%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Mar. 31, 2023	Mar. 20, 2023	Feb. 13, 2023	Jan. 12, 2023	Nov. 30, 2022	Nov. 30, 2021
Subsequent Events
Notes Payable, Current					$ 4,110,000	$ 3,053,000
Subsequent Event
Subsequent Events
Principal value	$ 150,000			$ 49,000
Convertible note			$ 62,387
Notes Payable, Current		$ 276,411
Original discount	15,000
Net debt discount	$ 135,000